Nicholas Adlard

List of Publications by Year
in descending order

21 papers	**288** citations	1039880 **9** h-index	940416 **16** g-index
21 all docs	**21** docs citations	**21** times ranked	**335** citing authors

#	Article	IF	Citations
1	Efficacy classification of modern therapies in multiple sclerosis. Journal of Comparative Effectiveness Research, 2021, 10, 495-507.	0.6	59
2	Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. Journal of Comparative Effectiveness Research, 2020, 9, 1255-1274.	0.6	44
3	Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 312-321.	0.4	34
4	A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis. Journal of Medical Economics, 2017, 20, 863-870.	1.0	24
5	Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England. Journal of Medical Economics, 2015, 18, 874-885.	1.0	23
6	Convergence yet Continued Complexity: A Systematic Review and Critique of Health Economic Models of Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Value in Health, 2015, 18, 925-938.	0.1	19
7	A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK. Journal of Medical Economics, 2017, 20, 474-482.	1.0	17
8	Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility. Journal of Medical Economics, 2017, 20, 962-973.	1.0	11
9	Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis. Current Medical Research and Opinion, 2020, 36, 1157-1166.	0.9	11
10	Secondary progressive multiple sclerosis: a systematic review of costs and health state utilities. Current Medical Research and Opinion, 2021, 37, 995-1004.	0.9	9
11	Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland. Pharmacoeconomics, 2021, 39, 563-577.	1.7	8
12	Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 66, 104031.	0.9	7
13	The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis. Current Medical Research and Opinion, 2020, 36, 1145-1156.	0.9	5
14	How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review. Neurology and Therapy, 2021, 10, 557-583.	1.4	4
15	Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses. Current Medical Research and Opinion, 2021, 37, 1-12.	0.9	4
16	Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada. Journal of Medical Economics, 2020, 23, 1525-1533.	1.0	3
17	Paucity and Inconsistency: A Systematic Review and Critique of Budget Impact Analyses of Disease-Modifying Therapies for Multiple Sclerosis in the UK and the Implications for Policy in the UK. Applied Health Economics and Health Policy, 2016, 14, 545-558.	1.0	2
18	Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732210857.	0.5	2

#	Article	IF	Citations
19	Systematic review and network meta‐analysis comparing ofatumumab with other disease‐modifying therapies available in Japan for the treatment of patients with relapsing multiple sclerosis. Clinical and Experimental Neuroimmunology, 2022, 13, 234-245.	0.5	2
20	Letter in reply. Journal of Comparative Effectiveness Research, 2021, 10, 1267-1269.	0.6	0
21	ENTIMOS: A Discrete Event Simulation Model for Maximising Efficiency of Infusion Suites in Centres Treating Multiple Sclerosis Patients. Applied Health Economics and Health Policy, 2022, , .	1.0	0